Skye Bioscience

Skye Bioscience is a biopharmaceutical company focused on developing proprietary cannabinoid derivatives to treat glaucoma and other diseases with significant unmet medical needs. Operating in the pharmaceutical industry, Skye Bioscience leverages its innovative approach to drug development to transform cannabinoids into safer, more effective pharmaceutical agents. The company primarily serves patients suffering from conditions that lack effective treatments, aiming to address these gaps with novel cannabinoid-based therapies. Skye Bioscience generates revenue through the development and commercialization of its proprietary drugs, targeting both domestic and international markets. The business model revolves around extensive research and development, clinical trials, and partnerships with healthcare providers and pharmaceutical companies to bring their products to market. By advancing their novel drugs, Skye Bioscience is working to unlock the potential of cannabinoids and bring important new medicines to patients in need.

Keywords: biopharmaceutical, cannabinoid derivatives, glaucoma treatment, unmet medical needs, drug development, pharmaceutical agents, novel drugs, healthcare, clinical trials, proprietary technology.